IN-SILICO DOCKING INVESTIGATION, SYNTHESIS AND INVITRO ANTICANCER STUDY OF BENZOXAZOLE DERIVATIVES
Abstract
Benzoxazole derivatives display broad spectrum of biological and pharmacological activities. The main objective of the present study was to explore newer molecules with potent biological activity like anticancer activity. Insilico screening was done and compound with no violation in Lipinski rule of five and good docking score are selected for wet lab synthesize. Benzoxazole derivatives were synthesized and are evaluated for invitro anticancer studies. Â Derivatives were synthesized using different benzaldehyde and anhydride derivative. The synthesized compounds were then established on the basis of IR, MASS and 1H NMR spectral data and screened for anticancer activity on Human breast cancer cell line (MCF-7). The derivative showed significant activity on cell line.
Keywords: Benzoxazole, dihydrophthalazine, anticancer, MTT assay.
Â
DOI
https://doi.org/10.22270/jddt.v4i6.1014Published
Abstract Display: 661
PDF Downloads: 861 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.